United Therapeutics Corporation (NASDAQ:UTHR) is one of the Top 10 Stocks Warren Buffett Would Buy in 2026.
On February 26, 2026, H.C. Wainwright raised the price target on United Therapeutics Corporation from $525 to $600 while maintaining a Buy rating. The company has announced that it is developing a soft mist inhaler for treprostinil, slated for a 2027 launch to treat PAH and PH-ILD. In the analyst note, H.C. Wainwright sees this as a strategic move to counter competitors like Yutrepia while evolving the Tyvaso franchise. The management reaffirmed its target of a $4 billion revenue run rate by late 2027, while it awaits the upcoming Phase 3 data for ralinepag and IPF treatments. The firm anticipates upside to this target.
On the same day, RBC Capital analyst Lisa Walter also raised United Therapeutics Corporation’s target price from $587 to $643 while keeping an Outperform rating on the stock. Similar to H.C. Wainwright, RBC Capital analyst also cited the new announcement for a soft mist inhaler for Treprostinil that could be preferred over DPIs.
Founded in 1996, United Therapeutics Corporation is a biotechnology company focused on rare diseases such as pulmonary arterial hypertension. Its co-headquarters are in Maryland and North Carolina.
READ NEXT: 10 Best Stocks to Buy in 2026 According to Reddit and 13 High-Quality S&P 500 Financial Stocks According to Hedge Funds.
Disclosure. None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center